FI960584L - Terapeuttisia peptidijohdannaisia - Google Patents

Terapeuttisia peptidijohdannaisia Download PDF

Info

Publication number
FI960584L
FI960584L FI960584A FI960584A FI960584L FI 960584 L FI960584 L FI 960584L FI 960584 A FI960584 A FI 960584A FI 960584 A FI960584 A FI 960584A FI 960584 L FI960584 L FI 960584L
Authority
FI
Finland
Prior art keywords
peptide derivatives
therapeutic peptide
therapeutic
derivatives
peptide
Prior art date
Application number
FI960584A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI960584A7 (fi
FI960584A0 (fi
Inventor
Sun Hyuk Kim
Zhengxin Dong
John E Taylor
Sylviane Moreau
Susan Riley Keyes
Original Assignee
Biomeasure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomeasure Inc filed Critical Biomeasure Inc
Publication of FI960584A7 publication Critical patent/FI960584A7/fi
Publication of FI960584A0 publication Critical patent/FI960584A0/fi
Publication of FI960584L publication Critical patent/FI960584L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
FI960584A 1993-08-09 1994-08-08 Terapeuttisia peptidijohdannaisia FI960584L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10419493A 1993-08-09 1993-08-09
PCT/US1994/008875 WO1995004752A1 (en) 1993-08-09 1994-08-08 Therapeutic peptide derivatives

Publications (3)

Publication Number Publication Date
FI960584A7 FI960584A7 (fi) 1996-02-08
FI960584A0 FI960584A0 (fi) 1996-02-08
FI960584L true FI960584L (fi) 1996-02-08

Family

ID=22299154

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960584A FI960584L (fi) 1993-08-09 1994-08-08 Terapeuttisia peptidijohdannaisia

Country Status (29)

Country Link
US (1) US5552520A (lt)
EP (3) EP1288224B1 (lt)
JP (3) JP3618750B2 (lt)
KR (1) KR100325972B1 (lt)
CN (1) CN1055700C (lt)
AT (3) ATE241643T1 (lt)
AU (1) AU689490B2 (lt)
CA (1) CA2168113C (lt)
CZ (3) CZ292586B6 (lt)
DE (3) DE69432758T2 (lt)
DK (3) DK1288224T3 (lt)
ES (3) ES2229045T3 (lt)
FI (1) FI960584L (lt)
GE (1) GEP20002146B (lt)
HU (1) HU224350B1 (lt)
LT (1) LT4078B (lt)
LV (1) LV11549B (lt)
MD (1) MD1591B2 (lt)
NZ (1) NZ271238A (lt)
PL (1) PL180612B1 (lt)
PT (2) PT1288223E (lt)
RO (1) RO117259B1 (lt)
RU (1) RU2133252C1 (lt)
SG (1) SG75092A1 (lt)
SI (2) SI0788509T1 (lt)
SK (1) SK15096A3 (lt)
UA (1) UA44707C2 (lt)
WO (1) WO1995004752A1 (lt)
ZA (1) ZA945966B (lt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2774769B2 (ja) * 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
EP0770623A4 (en) * 1995-03-20 2002-07-31 Kyowa Hakko Kogyo Kk INNOVATIVE CALCITON DERIVATIVES
US5824772A (en) * 1995-04-04 1998-10-20 Advanced Bioconcept, Inc. Fluorescent somatostatin
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6479457B2 (en) 1995-06-06 2002-11-12 Kinerton Limited Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5830431A (en) * 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US7078413B2 (en) 1996-04-19 2006-07-18 Wisconsin Alumni Research Foundation Compositions and methods of use for a bombesin peptide
US6492330B1 (en) * 1996-08-16 2002-12-10 National Institute Of Immunology Antiangiogenic drugs
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
US6124263A (en) * 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
EP1189942A1 (en) * 1999-06-25 2002-03-27 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Somatostatin agonists
US6864234B1 (en) 1999-06-25 2005-03-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Somatostatin agonists
EP1348444B1 (en) * 1999-08-18 2006-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Sustained release formulation of a peptide complexed with a polymer
US7109166B1 (en) * 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
AU2004200688B2 (en) * 1999-08-18 2007-01-25 Ipsen Pharma S.A.S. Sustained release formulation of a peptide
IES990700A2 (en) * 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
NZ526127A (en) * 1999-08-18 2005-02-25 Sod Conseils Rech Applic Use of a somatostatin analog in the manufacture of a medicament
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
MD2074G2 (ro) * 2000-12-29 2003-06-30 Юрий НИКИТИН Procedeu şi instalaţie de captare a vaporilor de carburant la staţiile de alimentare cu petrol, condensator al vaporilor de carburant utilizat în instalaţia menţionată
US20050124549A1 (en) 2001-03-06 2005-06-09 Uberti Ettore C.D. Method of modulating the proliferation of medullary thyroid carcinoma cells
CZ299362B6 (cs) * 2001-03-08 2008-07-02 The Administrators Of The Tulane Educational Fund Antagonisté somatostatinu
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
FR2833596B1 (fr) * 2001-12-14 2005-02-18 Aventis Pharma Sa Procede de preparation de derives d'echinocandine
US20040171070A1 (en) * 2002-05-20 2004-09-02 Ramagauri Bhikhabhai Peptide analysis using a solid support
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
EA008829B1 (ru) 2002-12-17 2007-08-31 Нэстек Фармасьютикал Кампани Инк. Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7741431B2 (en) * 2005-02-01 2010-06-22 The United States Of America As Represented By The Secretary Of The Army Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
US20090220587A1 (en) * 2005-02-01 2009-09-03 United State Army Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2118123B1 (en) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
CN104328100B (zh) 2008-06-12 2019-08-23 益普生生物创新有限公司 神经内分泌病的抑制
US10240138B2 (en) 2008-06-12 2019-03-26 Ipsen Bioinnovation Limited Polypeptides that bind to and inhibit secretion from growth hormone secreting cells
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
EP2408472A4 (en) * 2009-03-18 2013-01-02 Univ Leland Stanford Junior USE OF SOMATOSTATIN OR ANALOG IN COMBINATION WITH EXTERNAL RADIOTHERAPY
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
CN102770152B (zh) 2009-11-25 2016-07-06 阿瑞斯根股份有限公司 肽类的粘膜递送
JP6029472B2 (ja) 2010-01-13 2016-11-24 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． ソマトスタチン類似体（アナログ）の持続的放出のための医薬組成物の製造方法
CN102260352B (zh) * 2010-05-28 2013-11-20 山东先声麦得津生物制药有限公司 靶向性白细胞介素融合蛋白及其制备方法与应用
EP2399931A1 (fr) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Nouveaux composés octapeptidiques et leur utilisation thérapeutique
MX355543B (es) 2010-08-13 2018-04-20 Aileron Therapeutics Inc Star Macrociclos peptidomiméticos.
MX358886B (es) 2011-10-18 2018-08-31 Aileron Therapeutics Inc Macrociclos peptidomimeticos.
CN107216380A (zh) 2012-02-15 2017-09-29 爱勒让治疗公司 拟肽大环化合物
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
CN108659100A (zh) * 2017-03-28 2018-10-16 上海新生源医药集团有限公司 具有镇痛作用的多肽及其应用
CN113195524A (zh) 2018-10-11 2021-07-30 因塔西亚治疗公司 人类胰淀素类似物多肽和使用方法
KR102740870B1 (ko) * 2020-08-05 2024-12-12 주식회사 레미바이오 아스코르브산 유도체 및 이를 포함하는 조성물
CN120329530A (zh) * 2024-01-16 2025-07-18 元素驱动(杭州)生物科技有限公司 含有环酰亚胺结构的聚酯聚合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1246055A (en) * 1980-03-24 1988-12-06 Joseph H. Cort N-.omega.-substituted hormonogens of vasopressin and its synthetic analogs
DE3522638A1 (de) * 1985-06-25 1987-01-08 Diamalt Ag Neue somatostatin-derivate
DE3614833A1 (de) 1986-01-16 1987-07-23 Hoechst Ag Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
HU906341D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Process for producing peptonic derivatives modified with sugar and pharmaceutical preparatives containing these compounds as active substance
DK163689A (da) * 1988-04-08 1989-10-30 Sandoz Ag Peptidderivater
DE3910667A1 (de) * 1988-04-11 1989-10-19 Sandoz Ag Peptidderivate
DK375789A (da) 1988-08-18 1990-02-19 Syntex Inc Peptidderivater
FR2638968B1 (fr) * 1988-11-11 1994-10-07 Sandoz Sa Nouvelle utilisation therapeutique de la somatostatine et de ses analogues et derives
WO1991009837A1 (en) * 1989-12-22 1991-07-11 Commonwealth Scientific And Industrial Research Organisation Amino acids, peptides or derivatives thereof coupled to fats
GB9209032D0 (en) * 1992-04-25 1992-06-10 Ciba Geigy Ag New peptide derivatives

Also Published As

Publication number Publication date
JP2005015488A (ja) 2005-01-20
CA2168113A1 (en) 1995-02-16
LV11549A (lv) 1996-10-20
ATE399177T1 (de) 2008-07-15
SG75092A1 (en) 2000-09-19
JPH09501177A (ja) 1997-02-04
NZ271238A (en) 1997-10-24
SK15096A3 (en) 1996-07-03
HK1053313A1 (en) 2003-10-17
PT788509E (pt) 2003-10-31
PT1288223E (pt) 2005-03-31
EP1288224B1 (en) 2008-06-25
EP1288224A1 (en) 2003-03-05
CN1133047A (zh) 1996-10-09
EP1288223B1 (en) 2004-12-08
GEP20002146B (en) 2000-06-25
WO1995004752A1 (en) 1995-02-16
RO117259B1 (ro) 2001-12-28
CZ289552B6 (cs) 2002-02-13
EP1288223A1 (en) 2003-03-05
DE69435105D1 (de) 2008-08-07
EP0788509A4 (en) 1999-07-14
FI960584A7 (fi) 1996-02-08
MD960137A (en) 1999-01-31
LT4078B (en) 1996-12-27
PL312989A1 (en) 1996-05-27
LV11549B (en) 1997-04-20
DE69432758T2 (de) 2004-02-19
FI960584A0 (fi) 1996-02-08
DK1288224T3 (da) 2008-10-13
ES2229045T3 (es) 2005-04-16
EP0788509B1 (en) 2003-05-28
CZ39096A3 (en) 1996-11-13
KR100325972B1 (ko) 2002-07-27
DK1288223T3 (da) 2005-03-29
CN1055700C (zh) 2000-08-23
JP2004339237A (ja) 2004-12-02
ZA945966B (en) 1995-06-26
DE69434181T2 (de) 2005-12-01
SI9420051A (en) 1996-12-31
JP3785179B2 (ja) 2006-06-14
RU2133252C1 (ru) 1999-07-20
MD1591B2 (ro) 2001-01-31
DK0788509T3 (da) 2003-06-23
DE69434181D1 (de) 2005-01-13
AU689490B2 (en) 1998-04-02
EP0788509A1 (en) 1997-08-13
HUT73491A (en) 1996-08-28
PL180612B1 (pl) 2001-03-30
ES2196031T3 (es) 2003-12-16
JP3869439B2 (ja) 2007-01-17
HU9600281D0 (en) 1996-04-29
AU7481994A (en) 1995-02-28
SI0788509T1 (en) 2003-10-31
LT96025A (en) 1996-07-25
UA44707C2 (uk) 2002-03-15
CZ292586B6 (cs) 2003-10-15
CA2168113C (en) 2002-10-01
DE69432758D1 (en) 2003-07-03
HU224350B1 (hu) 2005-08-29
ATE241643T1 (de) 2003-06-15
ES2309131T3 (es) 2008-12-16
ATE284413T1 (de) 2004-12-15
CZ289590B6 (cs) 2002-02-13
US5552520A (en) 1996-09-03
JP3618750B2 (ja) 2005-02-09
HK1053314A1 (en) 2003-10-17

Similar Documents

Publication Publication Date Title
FI960584A7 (fi) Terapeuttisia peptidijohdannaisia
FI941398L (fi) Modifioituja peptidijohdannaisia
DE69230727D1 (de) Neuartige peptidderivate
FI932282L (fi) Protein c-derivat
FI922785A7 (fi) Terapeuttisia valmisteita
DK91192D0 (da) Protein
FI955828A7 (fi) Uusia peptidijohdannaisia
FI923379L (fi) Terapeutiska amider
FI943976A7 (fi) 5-aryyli-indolijohdannaiset
DK6893D0 (da) Peptid
FI961630A7 (fi) Terapeuttisia aineita
NO931831D0 (no) Farmasoeytiske blandinger
LV10962A (lv) Jauni peptidi
DE59407063D1 (de) Deodorierende zubereitungen
FI941758L (fi) Rekombitooppipeptidejä
FI945416L (fi) Dolastatiinijohdannaisia
FI942444A7 (fi) Terahydropyraanijohdannaisia
FI943885L (fi) Penaami-johdannaiset
FI924744L (fi) Terapeutiska aemnen
FI940109A7 (fi) Peptidejä
FI944044L (fi) Fenyylialkanoliamiinijohdannaiset
DE69429514D1 (de) Antiparasitäre präparate
FI923759L (fi) Terapeutiska bensazapinfoereningar
NO961589D0 (no) Farmasöytiske blandinger
FI963568A7 (fi) Peptidijohdannaisia

Legal Events

Date Code Title Description
FD Application lapsed
NF Re-establishment of lapsed right
FD Application lapsed